Dr. William Williams reports

BRIACELL THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING

Briacell Therapeutics Corp. intends to offer to sell common shares in a best-efforts public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the size or terms of the offering. The company is relying upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as Nasdaq.

ThinkEquity is acting as sole placement agent for the offering.

The company intends to use the net proceeds from the offering primarily for working capital requirements, general corporate purposes and the advancement of business objectives.

The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (file No. 333-276650), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the SEC) on Jan. 22, 2024, and declared effective on Jan. 31, 2024. The offering will be made only by means of a written prospectus. A preliminary prospectus supplement and accompanying prospectus describing the terms of the offering has been or will be filed with the SEC on its website. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from the offices of ThinkEquity, 17 State St., 41st floor, New York, N.Y., 10004. Before investing in this offering, interested parties should read in their entirety the preliminary prospectus supplement and the accompanying prospectus and the other documents that the company has filed with the SEC that are incorporated by reference in such preliminary prospectus supplement and the accompanying prospectus, which provide more information about the company and such offering.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.